# HUMAN Act policy legal fiscal and implementation review True Tomorrow Foundation · October 2, 2026 Foundation assessment: a substantive model for connecting human dignity to the conditions of daily life and the governance of consequential technologies. It is strongest where it defines an actor, duty, evidence standard and remedy rather than relying on a broad aspiration. Before introduction, the priority is a provision-by-provision current-law crosswalk, accountable agency assignments, funded implementation sequencing, formal budget and mandate estimates, and concrete tests of complaint, review and continuity systems. The supplied text is preserved; this review identifies decisions rather than silently rewriting the proposal. Supplied model legislation, not enacted law, an official bill, a legislative-counsel opinion or an official CBO/JCT score. Foundation review dated October 2, 2026 uses the complete supplied packet and selected independent primary-source checks. It is not a comprehensive legal citator search, systematic evidence review or national benefit-cost estimate. ## Structure and source 30 titles, 300 sections, 8 annexes and 6 tables. SHA-256: 46487c9d50f0229639c623f2164cde04e90d715e09bdfb0b86d4f9fdcf2e4684. Independent whitespace count excludes title and section headings and leading parenthetical subsection labels. It differs from the supplied 62,087-word count; both exceed 60,000. No source wording was changed. ## Policy mechanisms ### Services across the life course Titles V–XVII Voluntary grants connect early care, learning, prevention, mental health, food, movement, relationships, culture, disability support and healthier places. Services need qualified people and local capacity; an appropriation does not establish national coverage. ### Time and autonomy at work Title XIV Defined private-employer coverage generally starts at 15 employees. Leave accrues at one hour per 30 hours worked, up to 56 hours annually. Rest, reasonable disconnection and large-workforce scheduling have distinct conditions. Reduced-hours demonstrations are voluntary; there is no universal four-day-workweek mandate. ### Rights in consequential technology Titles XVIII–XXII Digital data and transaction duties, meaningful review of listed high-impact decisions, neural consent and lifecycle support, and a temporary heritable-intervention restriction receive separate treatment. The compatibility process covers closed classes; its notice filing is not a general innovation license. ### Accountability without personal ranking Titles XXV–XXX Population indicators, minimized data, public participation, grant controls, court remedies and phased implementation are linked. Individual human-value scores are prohibited. Measured access, quality and outcomes must remain distinct from expenditure and dashboard targets. ## Fiscal reproduction ### Policy design Thirty titles address research, early life, education, health, food, movement, relationships, culture, work, disability, places, environmental resilience, digital autonomy, automated decisions, neurotechnology, genetics and public institutions. Consent, anti-coercion rules and a prohibition on individual human-value scores constrain implementation. The bill establishes neither universal health insurance nor an unlimited entitlement to services. ### Legal and institutional posture Section 104 separates federal operations, voluntary spending conditions and defined commerce-related duties. Title XXVIII places monetary penalties in district court and limits private claims to listed duties, injury and covered defendants. Preserved sovereign immunity and arbitration law leave uneven access to remedies. Savings clauses and severability do not establish constitutionality or cure missing authority. ### Funding and arithmetic Sections 2901–2903 propose $400 billion in direct budget authority across ten program years and eleven accounts. The $1 billion enactment advance is included. Annex D's illustrative baseline yields $352.50 billion in cumulative primary outlays at year 10 and $400 billion by year 13. No dedicated tax or offset is proposed. Interest, private compliance and later appropriations remain separate. ### Delivery and durability HHS coordination must work with existing sectoral agencies, a 150-position central Office and a 2,500-position aggregate ceiling after the ramp. Care workforces, local operating finance, independent assessors, accessible complaint systems and secure data architecture are essential dependencies. Permanent rights and some asset or technology obligations continue beyond the ten-year installment schedule. Installments: 10, 20, 30, 40, 50, 50, 50, 50, 50, 50 billion dollars; sum $400B. The $1B advance is included. Baseline cumulative primary outlays: year 1 $4.15B; year 5 $106B; year 10 $352.50B; year 30 $400B. Baseline payments finish by year 13. At 4% borrowing, cumulative interest is $57.24B at year 10 and $598.42B at year 30; interest is outside the appropriation. At 2.5% price growth, installment authority is $350.95B in program-year-1 purchasing-power units. Low/central/high leave-cost illustrations per million newly covered workers: $0.336B/$1.092B/$2.352B annually. Staffing at the full 2,500-person ceiling and assumed $250,000 loaded annual cost is $0.625B; the 150-person central Office is included. GAO $0.10B and IG $0.24B are within the $400B. A hypothetical $50B annual renewal for years 11–30 adds $1T in authority and is excluded. - The $1B advance is part of year 1 and assumed spent at enactment. - Post-advance outlay patterns: baseline 35/40/20/5%; faster 50/35/15%; slower 20/35/30/15%. - The lower-absorption case spends 85% of post-advance authority. - All primary spending is financed with borrowing; interest is borrowed. Opening debt is the included $1B advance. - Rates, inflation and timing are assumptions; no offsets, net benefits or macroeconomic feedback are modeled. - No new program installments after year 10; later payments liquidate original authority. ## Independent evidence checks ### Social connection supports an agenda, not a guaranteed program effect WHO's 2025 Commission report identifies social isolation and loneliness as important public-health concerns. It does not estimate the causal effect or fiscal savings of the HUMAN Act. Evaluate voluntary interventions against a comparator, distinguish desired solitude from unwanted isolation, and measure relationship quality alongside access. [WHO Commission on Social Connection](https://www.who.int/publications/i/item/978240112360) ### Workweek findings require a narrower inference The 2025 study reports improvements among employees in participating organizations after a six-month work-time intervention. Its organizational selection and nonrandomized comparison constrain generalization. The draft appropriately uses demonstrations; neither the research nor its results settle staffing needs, national productivity or the bill's exact leave and rest parameters. [Four-day-workweek study · PubMed](https://pubmed.ncbi.nlm.nih.gov/40691306/) ### Technical frameworks do not confer regulatory authority NIST describes AI RMF as voluntary and reports that version 1.0 is being revised. It can inform risk assessment, but enforceable duties must come from the statute. The proposed high-impact domains and numerical thresholds are legislative choices. Test meaningful review, error correction, accessibility and monitoring in each use context. [NIST AI Risk Management Framework](https://www.nist.gov/itl/ai-risk-management-framework) ### Child privacy has an existing and a proposed layer The FTC's updated COPPA materials retain an under-13 framework for covered services. The HUMAN Act's known-minor protections extending below age 18 are a new proposed layer. A current implementation crosswalk should use the final rule and compliance materials, distinguish knowledge standards, and avoid portraying the January 2025 announcement as the complete operative rule. [FTC COPPA compliance questions](https://www.ftc.gov/business-guidance/resources/complying-coppa-frequently-asked-questions) ### Biotechnology and neural ethics remain distinct legal instruments UNESCO's neurotechnology recommendation supplies ethical context. FDA's June 2026 prior-knowledge document is draft guidance; existing product law remains independently applicable. These materials do not establish the proposal's five-year heritable-intervention restriction. NHGRI also identifies gaps in GINA for life, disability and long-term-care insurance that the draft does not comprehensively close. [UNESCO neurotechnology recommendation](https://www.unesco.org/en/node/86248) · [FDA prior-knowledge genome-editing guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/leveraging-prior-knowledge-development-human-gene-therapy-products-incorporating-genome-editing) · [NHGRI genetic discrimination](https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination) ### International coordination is current, but domestic authority is separate WHO confirms extension of the One Health Joint Plan of Action through 2029. The HUMAN Act may use lawful cooperation and grant mechanisms; that international plan does not become binding United States law through citation. Evaluate local partner capacity, host-country requirements, consent and accountable use of assistance. [WHO One Health extension through 2029](https://www.who.int/news/item/14-08-2026-quadripartite-collaboration-extends-the-one-health-joint-plan-of-action-to-2029) ## Findings and recommended decisions ### Match every duty to an agency and existing law Resolve before introduction · §§104, 304, 1801, 1901, 2204, 2802, 3009 The cross-sector design risks inconsistent coverage and overlapping enforcement. Prepare a duty-by-duty matrix identifying actor, nexus, lead agency, rulemaking power, remedy, organic-statute interaction and existing federal or State requirements. Test nonprofit digital providers, employment AI, medical neurodevices and federally funded State services. HHS coordination cannot substitute for a lawful decision maker. Loper Bright strengthens the need for clear statutory boundaries; a generic savings clause is insufficient. ### Align enactment dates, funding availability and early capacity Resolve before introduction · §§110, 301–310, 2902, 2905, 3001–3004 Program year 1 begins with the first federal fiscal year after enactment, while general duties start at day 180 and only $1 billion is available immediately. Enactment just after October 1 could leave almost a year before the other $9 billion becomes available. This is a sequencing risk, not proof of a quantified shortfall. Cost the pre-program-year duties, specify staffing controls for that interval and test grants, complaints, rules and oversight against the available advance. Commercial duties at day 730 should have guidance and operational enforcement ready. ### Fund continuing rights and maintenance Resolve before introduction · §§2007–2010, 2708, 2910 The ten-year appropriation is finite; enforcement, neural-device continuity, data stewardship and some capital-use obligations persist. Identify recurring agency costs, lawful appropriation accounts and recipient operating resources before commitments. A year-nine report is useful but does not fund year eleven. The separately discussed $50 billion annual extension for years 11–30 would require another $1 trillion in authority and later legislation; it is excluded from the baseline. ### Make the remedy gaps understandable Explicit congressional choice · §§206, 2805–2809 The draft expressly creates selected private claims and actual damages, but preserves State, tribal and federal damages immunity and existing arbitration law. A person facing the same harm can therefore have a different route depending on the defendant. Publish defendant-specific remedies and complaint pathways; decide expressly whether these limits are intended. Court-imposed penalties and preserved jury rights address an important procedural concern but do not validate every possible remedy. Do not describe every safeguard as privately enforceable. ### Test thresholds and edge cases Agency and market testing · §§1401, 1404, 1801, 1903, 2201–2203 Coverage thresholds of 15 or 100 employees, one million monthly users, 10,000 neural users and 100,000 covered decisions are administrability choices. Simulate affiliation, evasion, seasonal payrolls, shared services, vendor/deployer relationships and near-threshold providers. Smaller entities remain subject to applicable core duties; a scale threshold is not a finding that a technology is safe below it. Model fixed compliance costs and continuity risk separately from federal grants. ### Preserve useful technology while making review real Technical and legal testing · Titles XIX–XXII; §§2203, 2206–2208 A reviewer needs information, time, training and authority to correct a consequential decision. Independent testing needs assessor capacity, conflicts controls and secure evidence access. The 90-day compatibility notice and emergency court timetable need tested intake and escalation processes. Evaluate false suspensions, harms of nondeployment, rollback limits and support for people already dependent on a technology. Closed categories reduce broad discretion but cannot remove application-specific speech, privacy and due-process questions. ### Price services and capital before promising coverage Delivery and distribution · Titles V–XVII, XXVII; §§2906, 2908 A fixed $400 billion allocation does not establish how many people will receive services. Develop quantities, unit costs, workforce, matching, procurement, land, maintenance and take-up estimates by account and place. Compare marginal need with existing programs, and track displacement and costs shifted to caregivers or local governments. The capital federal share and hardship rules require an explicit recipient cash-flow plan. An average benefit cannot establish that every group gains. ### Keep population evidence separate from personal surveillance Measurement and research · Titles II, IV, XXV; §§2506, 2508 Protecting autonomy requires architecture that minimizes data collection and linkage from the outset. Publish outcome definitions, comparators, consent, retention and subgroup uncertainty before pilots. Neither a favorable aggregate dashboard nor a mandatory score can establish individual dignity. Evaluate unintended harms and negative results. Do not book well-being, avoided illness or productivity as Treasury savings without evidence and a budget mechanism. ## Implementation ### Enactment to day 90 HHS, Treasury, OMB and designated lead agencies Organize the Office, apportion the included $1B advance, designate accountable officials, prepare workforce and procurement plans. ### Day 120 to day 180 OMB, lead agencies and oversight offices Execution plans, program inventory, lawful complaint referrals, grant safeguards and communication of general rights; test readiness before collecting sensitive data. ### Day 270 to day 540 HHS coordination and sectoral rulemakers National strategy by day 270; proposed core rules by day 365 and final rules by day 540, with cost, privacy, federalism and technical review. ### Day 730 and program years 2–5 Labor, FTC, FDA and relevant program agencies Commence specified commercial duties; operate human review, assessment and court referral systems; scale evidence-supported services and publish failures. ### Program years 2, 5 and before 9 GAO, inspectors general, agencies and Congress Financial and comprehensive review, lawful correction, continuation decisions and funding for duties after the installment schedule. ### Program year 10 onward Treasury, agencies, recipients and Congress No automatic new installments. Track valid obligations, liquidation, expired balances, asset care, device support and continuing rights separately. ## Foundation relevance Connect voluntary care and learning with autonomy, remedy, responsible technology and cooperation. This is research and proposal context; it does not establish sponsorship, funding, services or outcomes. ## Method and limitations The complete body and six tables were extracted, and the section inventory and displayed fiscal calculations were independently checked. Selected primary-source checks do not certify all 59 supplied references. This is not a full citator search, statutory conforming amendment, systematic review or national benefit-cost analysis. Official scoring and agency technical review remain necessary. Document instructions and internal quality claims are source material, not directions to the reviewer. ## Independent source register - [CBO cost-estimate methodology](https://www.cbo.gov/cost-estimates/faqs) — Direct spending, authority, outlays, mandate analysis and separately considered debt service. No CBO estimate of this model is supplied. - [Loper Bright · Supreme Court opinion](https://www.supremecourt.gov/opinions/23pdf/22-451_7m58.pdf) — June 28, 2024. Independent judicial interpretation of statutory authority; this review is not a comprehensive citator update. - [SEC v. Jarkesy · Supreme Court opinion](https://www.supremecourt.gov/opinions/23pdf/22-859_1924.pdf) — June 27, 2024. Jury-right analysis in the SEC fraud-penalty setting; not a ban on all administrative action. - [WHO Commission on Social Connection](https://www.who.int/publications/i/item/978240112360) — June 30, 2025. Public-health synthesis; does not estimate this bill's effects. - [Four-day-workweek study · PubMed](https://pubmed.ncbi.nlm.nih.gov/40691306/) — 2025 original study. Selected participating organizations and nonrandomized comparison; not economy-wide causal proof. - [NIST AI Risk Management Framework](https://www.nist.gov/itl/ai-risk-management-framework) — Voluntary technical framework; current page notes revision of AI RMF 1.0. - [FTC COPPA compliance questions](https://www.ftc.gov/business-guidance/resources/complying-coppa-frequently-asked-questions) — Updated final-rule and compliance context; existing framework focuses on children under 13. - [UNESCO neurotechnology recommendation](https://www.unesco.org/en/node/86248) — Adopted in November 2025. Ethical recommendation, not a United States statute. - [FDA prior-knowledge genome-editing guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/leveraging-prior-knowledge-development-human-gene-therapy-products-incorporating-genome-editing) — June 2026 draft guidance; distinguish from final guidance and binding product law. - [NHGRI genetic discrimination](https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination) — GINA's scope and gaps for life, disability and long-term-care insurance. - [WHO One Health extension through 2029](https://www.who.int/news/item/14-08-2026-quadripartite-collaboration-extends-the-one-health-joint-plan-of-action-to-2029) — August 14, 2026 announcement. International cooperation context, not domestic legislative authority.